Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus

被引:31
作者
Niemeijer-Kanters, SDJM
Dallinga-Thie, GM
de Ruijter-Heijstek, FC
Algra, A
Erkelens, DW
Banga, JD
Jansen, H
机构
[1] Univ Utrecht, Med Ctr, Dept Internal Med, NL-3508 GA Utrecht, Netherlands
[2] Univ Utrecht, Med Ctr, Julius Ctr Patient Oriented Res, NL-3508 GA Utrecht, Netherlands
[3] Univ Utrecht, Med Ctr, Dept Neurol, NL-3508 GA Utrecht, Netherlands
[4] Erasmus Univ, Dept Internal Med, Rotterdam, Netherlands
[5] Erasmus Univ, Dept Biochem, Rotterdam, Netherlands
关键词
LDL particle size; type 2 diabetes mellitus; lipid-lowering therapy; HDL-cholesterol; triglycerides;
D O I
10.1016/S0021-9150(00)00642-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A preponderance of small dense LDL particles is strongly associated with the occurrence of atherosclerotic disease. Although several studies have documented an increased prevalence of small dense LDL particles in diabetes mellitus no data are available to show the effect of lipid-lowering treatment upon the improvement of LDL particle size. In the present study we examined the effect of lipid-lowering treatment, following an intensive lipid-lowering strategy for 30 weeks pursuing ADA recommended target lipid levels, on LDL particle size in 50 type 2 diabetic patients with moderate hyperlipidemia. At week 0, 24 patients (48%) were characterized by small dense LDL phenotype pattern B. After the treatment period a shift towards normal LDL particle size was observed in 17 patients but seven patients (29%) showed the more atherogenic LDL subclass pattern B. After treatment, plasma HDL-cholesterol was significantly lower (P < 0.05) in these patients compared to those who had LDL subclass pattern A. Multivariate regression analysis revealed VLDL-cholesterol or triglycerides and HDL3-cholesterol as independent determinants for LDL particle size. Change in HDL2-cholesterol was an independent determinant for change in LDL particle size. In conclusion, a strategy of intensive lipid-lowering, with the intention to reduce triglyceride levels below 1.7 mmol/l, may be insufficient to ensure improvement in LDL size in all patients. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:209 / 216
页数:8
相关论文
共 37 条
[1]  
*AM DIAB ASS, 1995, DIABETES CARE S1, V8, P86
[2]  
Amer Diabet Assoc, 1998, DIABETES CARE, V21, P179
[3]  
[Anonymous], 1992, Current Opinion in Lipidology
[4]   GENETIC EPIDEMIOLOGY OF LOW-DENSITY-LIPOPROTEIN SUBCLASS PHENOTYPES [J].
AUSTIN, MA .
ANNALS OF MEDICINE, 1992, 24 (06) :477-481
[5]  
Bachorik P S, 1986, Methods Enzymol, V129, P78
[6]  
CAMEJO G, 1990, CURR OPIN LIPIDOL, V1, P431
[7]   HYPERTRIGLYCERIDEMIA AS A RISK FACTOR OF CORONARY HEART-DISEASE MORTALITY IN SUBJECTS WITH IMPAIRED GLUCOSE-TOLERANCE OR DIABETES - RESULTS FROM THE 11-YEAR FOLLOW-UP OF THE PARIS PROSPECTIVE-STUDY [J].
FONTBONNE, A ;
ESCHWEGE, E ;
CAMBIEN, F ;
RICHARD, JL ;
DUCIMETIERE, P ;
THIBULT, N ;
WARNET, JM ;
CLAUDE, JR ;
ROSSELIN, GE .
DIABETOLOGIA, 1989, 32 (05) :300-304
[8]   Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women [J].
Gardner, CD ;
Fortmann, SP ;
Krauss, RM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (11) :875-881
[9]   Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction [J].
Gaziano, JM ;
Hennekens, CH ;
ODonnell, CJ ;
Breslow, JL ;
Buring, JE .
CIRCULATION, 1997, 96 (08) :2520-2525
[10]   Increased low density lipoprotein oxidation in stable kidney transplant recipients [J].
Ghanem, H ;
vandenDorpel, MA ;
Weimar, W ;
ManintVeld, AJ ;
Elkannishy, MH ;
Jansen, H .
KIDNEY INTERNATIONAL, 1996, 49 (02) :488-493